Para-Bromophenacyl bromide alleviates airway hyperresponsiveness and modulates cytokines, IgE and eosinophil levels in ovalbumin-sensitized and -challenged mice

Parabromophenacyl Bromide Inhibits Subepithelial Fibrosis by Reducing TGF-β₁ in a Chronic Mouse Model of Allergic Asthma

“…PBPB inhibited PLA2 activity and various features of allergic airway inflammation such as methacholine-induced airway constriction, Th2 cytokines, serum IgE levels and airway eosinophilia [9]. As it is well known that asthma is a chronic condition and that most patients continue to visit the clinic after the development of asthma, the identification of drug molecules to reduce airway remodeling would be a good strategy.…”

“…After acclimatization, the mice were divided into 4 groups with 6 mice in each, i.e group 1: sham + VEH [alum-sensitized, PBS-challenged and vehicle, i.e. treated with 50% ethanol)], group 2: OVA + VEH [OVA (chicken egg ovalbumin, grade V)-sensitized, OVA-challenged and VEH-treated], group 3: OVA + PBPB (OVA-sensitized, OVA-challenged and treated with 1 mg/kg PBPB twice a day, a dose based on our earlier study [9]) and group 4: OVA + Dexa (OVA-sensitized, OVA-challenged and treated with 0.75 mg/kg Dexa once a day). Each mouse was sensitized with 50 µg OVA adsorbed in 4 mg aluminium hydroxide or in 4 mg aluminium hydroxide only.…”

“…Thus, in this context, we initially identified a potent antiasthmatic agent, parabromophenacyl bromide (PBPB), in an acute mouse model of asthma [9]. PBPB is a phospholipase A2 (PLA2) inhibitor, and has been found to inhibit AHR and inflammation [9].…”

“…PBPB is a phospholipase A2 (PLA2) inhibitor, and has been found to inhibit AHR and inflammation [9]. Most remarkably, it worked potentially in both preventive (i.e.…”

“…inhibited development) as well as reversal (i.e. attenuated the developed) capacities on asthmatic features in our models [9]. However, the effect of PBPB on airway remodeling has not been studied so far.…”